BeOne Medicines Ltd. (SHA:688235)

Market Cap	259.17B
Revenue (ttm)	30.30B
Net Income (ttm)	-2.85B
Shares Out	n/a
EPS (ttm)	-26.87
PE Ratio	n/a
Forward PE	176.10
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,380,289
Average Volume	2,730,582
Open	250.30
Previous Close	249.46
Day's Range	244.02 - 250.30
52-Week Range	129.82 - 268.47
Beta	0.28
RSI	58.10
Earnings Date	Aug 6, 2025

About Accolade

BeOne Medicines Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company’s commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton’s Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; and PARTRUVIX, a selective small molecule inhibitor of PARP1 and PARP2 enzymes that is being evaluated ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2010
• Employees: 11,000
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 688235

Financial Performance

In 2024, BeOne Medicines's revenue was $3.81 billion, an increase of 54.96% compared to the previous year's $2.46 billion. Losses were -$644.79 million, -26.87% less than in 2023.